Oppenheimer & Co. Inc. Makes New Investment in Immunocore Holdings plc (NASDAQ:IMCR)

Oppenheimer & Co. Inc. acquired a new stake in Immunocore Holdings plc (NASDAQ:IMCRFree Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 19,230 shares of the company’s stock, valued at approximately $1,314,000.

Several other institutional investors also recently modified their holdings of the company. Exchange Traded Concepts LLC grew its holdings in Immunocore by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 2,656 shares of the company’s stock worth $181,000 after purchasing an additional 674 shares during the period. JGP Global Gestao de Recursos Ltda. bought a new position in shares of Immunocore during the 4th quarter worth approximately $230,000. NEOS Investment Management LLC acquired a new position in shares of Immunocore during the 4th quarter worth approximately $262,000. China Universal Asset Management Co. Ltd. raised its stake in Immunocore by 366.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,900 shares of the company’s stock valued at $266,000 after acquiring an additional 3,064 shares during the period. Finally, Graham Capital Management L.P. acquired a new stake in Immunocore during the 3rd quarter valued at $411,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on IMCR shares. Canaccord Genuity Group upped their price objective on shares of Immunocore from $63.00 to $67.00 and gave the company a “hold” rating in a report on Thursday, May 9th. Oppenheimer restated an “outperform” rating and set a $87.00 price objective (up from $85.00) on shares of Immunocore in a research report on Thursday, February 29th. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Immunocore in a report on Wednesday, June 5th. JPMorgan Chase & Co. increased their target price on Immunocore from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Finally, Mizuho reduced their price target on Immunocore from $90.00 to $88.00 and set a “buy” rating for the company in a research note on Monday, May 13th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Immunocore currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.85.

Read Our Latest Analysis on IMCR

Immunocore Stock Performance

IMCR opened at $40.44 on Tuesday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 5.94 and a current ratio of 5.96. Immunocore Holdings plc has a 52-week low of $39.61 and a 52-week high of $76.98. The firm has a market cap of $2.02 billion, a P/E ratio of -33.15 and a beta of 0.84. The business’s fifty day moving average is $54.39 and its 200-day moving average is $61.79.

Immunocore (NASDAQ:IMCRGet Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12). The firm had revenue of $70.30 million for the quarter, compared to analyst estimates of $70.72 million. Immunocore had a negative return on equity of 16.54% and a negative net margin of 22.60%. The company’s quarterly revenue was up 27.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.35) earnings per share. Sell-side analysts expect that Immunocore Holdings plc will post -1.88 EPS for the current fiscal year.

Immunocore Company Profile

(Free Report)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

Read More

Want to see what other hedge funds are holding IMCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunocore Holdings plc (NASDAQ:IMCRFree Report).

Institutional Ownership by Quarter for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.